ABSTRACT: Pluripotent mesenchymal stem cells can undergo lineage-specific differentiation in adult organisms. However, understanding of the factors and mechanisms that drive this differentiation is limited. We show the novel ability of specific oxysterols to regulate lineage-specific differentiation of mesenchymal stem cells into osteogenic cells while inhibiting their adipogenic differentiation. Such effects may have important implications for intervention with osteoporosis.
INTRODUCTION

M
ESENCHYMAL TISSUE REGENERATION during adult life is highly dependent on a population of pluripotent stem cells commonly known as mesenchymal stem cells or marrow stromal cells (MSCs). (1, 2) These cells are present in a variety of tissues and are prevalent in bone marrow stroma. (3, 4) They can be readily isolated and expanded in culture, and on treatment with a variety of agonists, they can differentiate into lineagespecific cells including osteoblasts, chondrocytes, myocytes, adipocytes, and fibroblasts. (1) (2) (3) (4) MSCs are thought to be an excellent potential tool for interventions in many diseases that result from reduced or impaired functioning of these cells. (5, 6) Such interventions may include regeneration of defective extracellular matrix by systemic infusion of MSCs in individuals with generalized defects such as in osteogenesis imperfecta, (7, 8) repair of damaged tissues such as bone and cartilage by localized injection into the affected areas, (9, 10) and the therapeutic delivery of specific genes to diseased tissues. (11) All this, however, requires an understanding of the factors and molecular mechanisms involved in determining lineagespecific differentiation of MSCs and the identification of new strategies for driving lineage-specific differentiation in vitro and in vivo.
One situation in which MSCs might be used in human disease is in age-related and postmenopausal osteoporosis, where the decreased number and osteogenic activity of osteoprogenitor MSCs, in part, leads to decreased bone formation. (6, (12) (13) (14) A reduction in bone formation by osteoblasts in the face of increased bone resorption by osteoclasts in these disorders results in decreased bone mass, increased susceptibility to fractures, and impaired fracture healing. (14) Therefore, the systemic and/or local application of osteoprogenitor MSCs, or factors that enhance their osteogenic differentiation, could be of great potential benefit in boosting bone forming capacity in osteoporosis. Future improved treatment of osteoporosis will likely require the use of bone anabolic agents that can enhance the osteogenic differentiation and bone-forming capacity of osteoblastic precursor cells, and hence increase bone mass and reduce fracture risk. (15) (16) (17) Several growth factors and hormones have been tested in this regard, including bone morphogenetic protein (BMP), growth hormone, and parathyroid hormone (PTH). (15, 16) BMPs play critical roles in the differentiation of MSCs into osteoblasts both in vitro and in vivo. (18, 19) BMP2 is the most potent known inducer of bone formation in vivo, and it enhances the differentiation of osteoprogenitor and non-osteoprogenitor precursors into cells with osteoblastic phenotype. (20) The use of BMPs in fracture healing is currently hampered by the large concentrations of the recombinant protein necessary to induce adequate bone formation. (20) Currently, only PTH, which on intermittent injection increases bone mass and reduces bone fracture incidence, has been approved by the Food and Drug Administration (FDA). However, because of its potential adverse side effects and cost, it is currently only used for severely osteoporotic patients. Hence identification of novel factors and strategies for enhancing bone formation is currently an area of intense investigation.
Because MSCs are the common progenitors for both osteoblasts and adipocytes, (1) (2) (3) (4) reductions in the number of osteoblastic cells in aging and osteoporosis have been attributed, in part, to an increased differentiation of these common progenitor cells into adipocytes rather than osteoblasts. (14) It has been observed that the numbers of adipocytes in the bone marrow increases in parallel with a decrease in the number of osteoblasts in a variety of types of osteoporosis. (21) Moreover, the volume of adipose tissue in bone increases with age in normal subjects and is substantially elevated in age-related osteoporosis, (22) with the number of adipocytes adjacent to bone trabeculae increasing in parallel to the degree of trabecular bone loss. (23) Based on this and similar observations, it has been suggested that bone loss in age-related osteoporosis is at least in part caused by a shift in MSC differentiation from the osteoblastic to the adipocytic pathway. (14, 21) If this is true, it is possible that intervening in this apparent shift in lineagespecific differentiation of MSCs could increase the number of cells capable of undergoing differentiation into functioning osteoblasts. (21) Oxysterols form a large family of oxygenated derivatives of cholesterol that are present in the circulation and in human and animal tissues. (24 -26) These compounds may be formed either by auto-oxidation, as a secondary byproduct of lipid peroxidation, or by the action of specific monooxygenases, most of which are members of the cytochrome P450 family of enzymes. (27) In addition, oxysterols may be derived from dietary intake. (28) Oxysterols have potent effects in physiologic and pathological processes including cholesterol metabolism, inflammation, apoptosis, steroid production, and atherosclerosis. (24 -26,29) Moreover, because of the abundance of cholesterol in living organisms, the pro-oxidant nature of our cellular metabolic processes, and the multitude of enzymatic and non-enzymatic pathways for oxysterol production, we speculate that oxysterols may play additional, as yet unidentified, roles in biological systems. Recently, several reports have noted the possible role of oxysterols in cellular differentiation. (30 -32) For example, the oxysterols 22(R)-and 25-hydroxycholesterol induce the differentiation of human keratinocytes in vitro, (30, 31) whereas monocyte differentiation is induced by the oxysterol 7-ketocholesterol. (32) We previously reported that products of the cholesterol biosynthetic pathway are important for the proper osteogenic differentiation and activity of MSCs. (33) Because oxysterols may be a derivative of the endogenous cellular cholesterol biosynthetic pathway, (25) (26) (27) we hypothesized that the oxysterols generated by osteoprogenitor cells, as well as those derived from exogenous sources, may be involved in their osteogenic differentiation. In this report, we present the first line of evidence for osteogenic activity of specific oxysterols and their ability to inhibit adipogenic differentiation. In addition, we show the synergistic interaction of these oxysterols with BMP2.
MATERIALS AND METHODS
Materials
Oxysterols, ␤-glycerophosphate (␤GP), silver nitrate, and Oil red O were obtained from Sigma (St Louis, MO, USA); RPMI 1640, ␣-MEM, and DMEM were from Irvine Scientific (Santa Ana, CA, USA); and FBS was from Hyclone (Logan, UT, USA). PD98059 was purchased from BI-OMOL Research Labs (Plymouth Meeting, PA, USA); TO-901317, SC-560, NS-398, Ibuprofen, and Flurbiprofen were from Cayman Chemical (Ann Arbor, MI, USA); ACA and AACOCF3 were from Calbiochem (La Jolla, CA, USA); and recombinant human BMP2 was from R&D Systems (Minneapolis, MN, USA). Antibodies to phosphorylated and native extracellular signal-regulated kinases (ERKs) were obtained from New England Biolabs (Beverly, MA, USA) and troglitazone was from Sankyo (Tokyo, Japan).
Cells
The M2-10B4 mouse marrow stromal cell line obtained from American Type Culture Collection (Rockville, MD, USA) was derived from bone marrow stromal cells of a (C57BL/6J ϫ C3H/HeJ) F1 mouse and supports human and murine myelopoiesis in long-term cultures (as per ATCC). These cells were cultured in RPMI 1640 containing 10% heat-inactivated FBS and supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 U/ml streptomycin (all from Irvine Scientific). The MC3T3-E1 mouse preosteoblastic cell line was purchased from ATCC and cultured in ␣-MEM containing 10% heat-inactivated FBS and supplements as described above. C3H-10T1/2 mouse pluripotent embryonic fibroblast cells were kindly provided by Dr Kristina Bostrom (UCLA) and were cultured in DMEM
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containing 10% heat-inactivated FBS and supplements as described above. Primary mouse marrow stromal cells were isolated from male 4-to 6-month-old C57BL/6J mice and cultured and propagated as previously reported. (34) Alkaline phosphatase activity assay Colorimetric alkaline phosphatase (ALP) activity assay on whole cell extracts was performed as previously described. (34) von Kossa and Oil red O staining Matrix mineralization in cell monolayers was detected by silver nitrate staining as previously described. (34) Oil red O staining for detection of adipocytes was performed as previously described. (34) 
Ca incorporation assay
Matrix mineralization in cell monolayers was quantified using the 45 Ca incorporation assay as previously described. (35) 
Western blot analysis
After treatments, cells were lysed in lysis buffer, protein concentrations were determined using the Bio-Rad protein assay (Hercules, CA, USA), and SDS-PAGE was performed as previously described. (34) Probing for native and phosphorylated ERKs was performed as previously reported. (34) 
RNA isolation and Northern blot analysis
After treatment of cells under appropriate experimental conditions, total RNA was isolated using the RNA isolation kit from Stratagene (La Jolla, CA, USA). Total RNA (10 mg) was run on a 1% agarose/formaldehyde gel and transferred to Duralon-UV membranes (Strategene) and crosslinked with ultraviolet light. The membranes were hybridized overnight at 60°C with a 32 P-labeled mouse osteocalcin cDNA probe, (36) mouse lipoprotein lipase (LPL), mouse adipocyte protein 2 (aP2) PCR-generated probes, and human 28S and 18S rRNA probes obtained from Geneka Biotechnology (Montreal, Quebec, Canada) and Maxim Biotech (San Francisco, CA, USA), respectively. The PCR products were generated using primer sets synthesized by Invitrogen (Carlsbad, CA, USA) with the following specifications: mouse aP2 gene (accession no. M13261); sense (75-95) 5Ј-CCAGGGAGAACCAAAGTTGA-3Ј, antisense (362-383) 5Ј-CAGCACTCACCCACTTCTTTC-3Ј, generating a PCR product of 309 bp. Mouse LPL (accession no. XM_134193); sense (1038 -1058) 5Ј-GAATGAAGAAAA-CCCCAGCA-3Ј, antisense (1816 -1836) 5Ј-TGGGCCA-TTAGATTCCTCAC-3Ј, generating a PCR product of 799 bp. The PCR products were gel-purified and sequenced by the UCLA sequencing core, showing the highest similarity to their respective GenBank entries. After hybridization, the blots were washed twice at room temperature with 2ϫ SSC and 0.1%SDS and twice at 60°C with 0.5ϫ SSC and 0.1% SDS and exposed to X-ray film. The extent of gene induction was determined by densitometry.
BMP2 ELISA
Conditioned medium from M2 cells cultured in 24-well plates was prepared after treatment with oxysterols or control buffer for 24 or 48 h, followed by rinsing the cells to remove the treatment media and replacing it with 0.5 ml RPMI containing 0.1% bovine serum albumin (BSA)/well. After 24 h, the conditioned medium was collected, centrifuged to remove debris, and used in the BMP2 ELISA immunoassay according to the manufacturer's instructions (R&D Systems).
Statistical analyses
Computer-assisted statistical analyses were performed using the StatView 4.5 program. All p values were calculated using ANOVA and Fisher's projected least significant difference (PLSD) significance test. A value of p Ͻ 0.05 was considered significant.
RESULTS
Novel osteogenic activities of oxysterols
To begin testing our hypothesis, we examined the effects of oxysterols on indices of osteoblastic differentiation in in vitro cultures of MSCs. In cultures of MSCs in vitro, stimulation of ALP activity, osteocalcin gene expression, and mineralization of cell colonies are indices of increased differentiation into osteoblast phenotype. (37, 38) We found that specific oxysterols, namely 22(R)-hydroxycholesterol (22R), 20(S)-hydroxycholesterol (20S), and 22(S)-hydroxycholesterol (22S), induced ALP activity, an early marker of osteogenic differentiation, in pluripotent M2-10B4 murine MSCs (M2; Fig. 1A ). This effect was specific, because other oxysterols, including 7-ketocholesterol (7K), did not induce ALP activity in these cells (Fig. 1A) . The induction of ALP activity was both dose-and timedependent at concentrations between 0.5 and 10 M, and showed a relative potency of 20S Ͼ 22S Ͼ 22R. A 4-h exposure to these oxysterols followed by replacement with osteogenic medium without oxysterols was sufficient to induce ALP activity in M2 cells, measured after 4 days in culture.
Although induction of ALP activity is an early marker of osteogenic differentiation and plays an important role in both the differentiation and eventual mineralization processes, (39) this response was not sufficient for the induction of mineralization in M2 cells by individual oxysterols. Individual oxysterols (22R, 20S, and 22S) at concentrations between 0.5 and 10 M were unable to induce mineralization after as many as 14 days of exposure, despite their ability to cause large increases in ALP activity measured 4 days after treatment (data not shown). The individual oxysterols also had minimal to no effect on osteocalcin gene expression after as many as 14 days of treatment (data not shown). However, ALP activity (Fig. 1B) Ca incorporation assay as previously described. Results from a representative of four experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.01 for C vs. oxysteroltreated cultures). (E) M2 cells at confluence were treated with control vehicle (C) or a combination of 22R and 20S oxysterols (Ox; 5 M each) in osteogenic medium. After 4 and 8 days, total RNA from duplicate samples was isolated and analyzed for osteocalcin (Osc) and 28S rRNA expression by Northern blotting as described. Data from densitometric analysis of the Northern blot is shown in F as the average of duplicate samples, normalized to 28S rRNA. (G) C3H10T1/2 cells at confluence were treated in osteogenic medium with control vehicle (C) or a combination of 22R and 20S oxysterols, at the indicated concentrations. ALP activity was measured after 3 days as described above. Results from a representative of three experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.01 for C vs. oxysterols). (H) Primary MSCs at confluence were treated in osteogenic medium with control vehicle (C) or a combination of 22R and 20S oxysterols, at the indicated concentrations. After 10 days, matrix mineralization in cultures was quantified using a 45 Ca incorporation assay as described earlier.
Results from a representative of three experiments are reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.05 for C vs. oxysterols).
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hydroxycholesterol has osteogenic effects on osteoblast precursor cells. Although stimulation of MSCs by BMP2 can enhance their osteogenic differentiation, (37) the osteogenic effects of the oxysterols were not caused by the induction of BMP2 expression in M2 cells. RT-PCR analysis of BMP2 mRNA expression in M2 cells treated for 4 
. We speculate that in light of our RT-PCR and ELISA data that did not show any induction of BMP2 by oxysterols, the inhibition of response to oxysterols by noggin might be caused by inhibition of synergism between oxysterols and BMP2 present in FBS. Alternatively, oxysterols may induce the expression of other members of the BMP family that can interact with noggin, such as BMP4 and BMP7, the expression of which would not be detected by our BMP2-specific ELISA assay.
Synergistic osteogenic effects of oxysterols with BMP2
As with other osteoprogenitor cells, BMP2 is able to induce osteoblastic differentiation of M2 cells in vitro. (40) Interestingly, we found that osteogenic combination of 22R ϩ 20S oxysterols acted synergistically with BMP2 in inducing ALP activity ( Fig. 2A) , osteocalcin mRNA expression (Figs. 2C and 2D) , and mineralization by M2 cells (Fig. 2B) . Although synergism in stimulating ALP activity was found when individual oxysterols 20S, 22S, and 22R were added with BMP2, synergy in induction of mineralization was only produced when oxysterols were added in combinations of 22R ϩ 20S or 22S ϩ 20S oxysterols with BMP2.
Novel anti-adipogenic activities of oxysterols
Adipogenesis of adipocyte progenitors including MSC is regulated by the transcription factor peroxisome proliferator activated receptor ␥ (PPAR␥), which on activation by ligand-binding, regulates transcription of adipocyte-specific genes. (41) We previously reported that, as expected with MSCs, M2 cells have the ability to undergo adipogenic differentiation in response to the PPAR␥ activator, Troglitazone (Tro). (34) In M2 cells treated with Tro to induce adipogenesis, 20S, 22S, and 22R, alone or in combination, inhibited adipogenesis (Figs. 3A and 3B) . The relative antiadipogenic potency of these oxysterols was similar to their relative potency in stimulating ALP activity in M2 cells, with 20S Ն 22S Ͼ 22R. Similar to its lack of osteogenic effect, 7K was also unable to inhibit adipogenesis in M2 cells (data not shown). Inhibition of adipogenesis was also assessed by an inhibition of the expression of the adipogenic genes LPL and aP2 by 20S (Figs. 3C and 3D) . However, addition of the oxysterols to already formed adipocytes in M2 cell cultures did not reduce the number of adipocytes after 8 days of treatment (data not shown), suggesting that the oxysterols were active only at the early stages of adipogenesis. Inhibitory effects of these three oxysterols on adipogenesis were also demonstrated using C3H10T1/2 and primary mouse MSC, in which adipogenesis was induced either by Tro or a standard adipogenic cocktail consisting of dexamethasone and isobutylmethylxanthine (data not shown).
Mechanism of osteogenic activity of oxysterols
Mesenchymal cell differentiation into osteoblasts is regulated by cyclo-oxygenase (COX) activity. (42) (43) (44) We examined the possible role of COX in mediating the osteogenic effects of oxysterols on M2 cells. In the presence of FBS, which corresponds to our experimental conditions, M2 cells in culture express both COX-1 and COX-2 mRNA at all stages of osteogenic differentiation (data not shown). Consistent with the role of COX in osteogenesis, our studies showed that the COX-1 selective inhibitor SC-560, at 1-20
FIG. 2. Synergistic osteogenic effects of oxysterols and BMP2 in
MSCs. (A) M2 cells at confluence were treated with control vehicle (C), 50 ng/ml recombinant human BMP2, or a combination of 22R and 20S oxysterols (RS, 2.5 M each), alone or in combination in osteogenic medium as described in Fig. 1 . ALP activity was measured after 2 days as previously described. Results from a representative of four experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.001 for BMP ϩ RS vs. BMP and RS alone). (B) M2 cells were treated as described in A. After 10 days, matrix mineralization in cultures was quantified using a 45 Ca incorporation assay as previously described.
Results from a representative of four experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (p Ͻ 0.01 for BMP ϩ RS vs. BMP and RS alone). (C) M2 cells were treated under similar conditions as those described above. After 8 days, total RNA was isolated and analyzed for osteocalcin (Osc) and 18S rRNA expression by Northern blotting as previously described. Data from densitometric analysis of the Northern blot is shown in D as the average of duplicate samples, normalized to 18S rRNA.
834
KHA ET AL.
M, significantly inhibited the osteogenic effects of the 22R ϩ 20S and 22S ϩ 20S oxysterol combinations. SC-560 inhibited oxysterol-induced ALP activity (Fig. 4A ), mineralization (Fig. 4B) , and osteocalcin gene expression (Figs. 4C and 4D). Although less effective than SC-560, the nonselective COX inhibitors, ibuprofen and flurbiprofen, at nontoxic doses of 1-10 M, also significantly inhibited the osteogenic effects of 22R ϩ 20S oxysterol combination by 25-30%. In contrast, the selective COX-2 inhibitor, NS-398, at the highest nontoxic dose of 20 M, had only negligible inhibitory effects. SC-560 (10 M) also inhibited the synergistic induction of ALP activity by oxysterols and BMP2 (Fig. 4G) . Furthermore, the osteogenic effects of the oxysterol combination on ALP activity (Fig. 4E ) and mineralization (Fig. 4F) were also inhibited by the general phospholipase A 2 (PLA 2 ) inhibitor ACA and by the selective cytosolic PLA 2 inhibitor, AACOCF3 (AAC). Moreover, rescue experiments showed that the effects of the COX-1 and PLA 2 inhibitors on oxysterol-induced ALP activity were reversed by the addition of 1 M PGE 2 ( Fig. 4H ) and 25 M arachidonic acid (Fig. 4I) , respectively. The ERK pathway is another major signal transduction pathway previously associated with osteoblastic differentiation of osteoprogenitor cells. (45, 46) Interestingly, the 20S oxysterol used alone or in combination with 22R oxysterol caused a sustained activation of ERK1 and ERK2 in M2 cells (Figs. 5A and 5B). Inhibition of the ERK pathway by the inhibitor PD98059 inhibited oxysterol-induced mineralization (Fig. 5C ) but not ALP activity or osteocalcin mRNA expression in M2 cell cultures (data not shown). These results suggest that sustained activation of ERK is important in regulating certain specific, but not all, osteogenic effects of oxysterols.
Liver X receptors (LXR) are nuclear hormone receptors that, in part, mediate certain cellular responses to oxysterols, including 22R and 20S, but not 22S. (47, 48) LXR␣ is expressed in a tissue-specific manner, whereas LXR␤ is ubiquitously expressed. (47, 48) By Northern blot analysis, we demonstrated the expression of LXR␤, but not LXR␣, in confluent cultures of M2 cells (data not shown). To assess the possible role of LXR in mediating the effects of osteogenic oxysterols, we examined whether activation of LXR␤ by the pharmacologic LXR ligand TO-901317 (TO) had effects similar to those exerted by 22R and 20S in M2 cells. Interestingly, in contrast to 22R and 20S, TO at 1-10 M caused a dose-dependent inhibition of ALP activity in M2 cells (control [C]: 18 Ϯ 2; ligands used at 10 M: 22R ϭ 45 Ϯ 5; 20S ϭ 140 Ϯ 12; and TO ϭ 3 Ϯ 0.5 activity units/mg protein; p Ͻ 0.01 for C versus all ligands). Furthermore, TO treatment did not induce osteocalcin gene expression or mineralization after 10 days (data not shown). Therefore, the osteogenic effects of the oxysterols on M2 cells seem to be independent of the LXR receptor, as suggested by the potent osteogenic activity of the non-LXR oxysterol ligand 22S and the lack of osteogenic effects in response to the LXR ligand TO. SC for 4 h, followed by the addition of RS in the presence or absence of SC as described above. After 8 days, total RNA was isolated and analyzed for osteocalcin (Osc) and 18S rRNA expression by Northern blotting as previously described. Data from densitometric analysis of the Northern blot is shown in D as the average of duplicate samples, normalized to 18S rRNA. (E) M2 cells at confluence were pretreated for 2 h with control vehicle (C) or PLA 2 inhibitors ACA (25 M) and AACOCF3 (AAC, 20 M) in osteogenic medium. Next, a combination of 22R and 20S oxysterols (RS, 2.5 M) was added in the presence or absence of the inhibitors as indicated. After 3 days, ALP activity was measured as previously described. Data from a representative of three experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.01 for RS vs. RS ϩ ACA and RS ϩ AAC). (F) M2 cells were treated as described in E. After 10 days, matrix mineralization in cultures was quantified using a 45 Ca incorporation assay as previously described. Results from a representative of three experiments are shown, reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.01 for RS vs. RS ϩ ACA and RS ϩ AAC). (G) M2 cells at confluence were treated in osteogenic medium with control vehicle (C), rhBMP2 (BMP, 50 ng/ml), and oxysterol combination 22R ϩ 20S (RS, 2.5 M) alone or in combination. Pretreatment of some cells with SC-560 (SC, 10 M) was done for 2 h before the addition of BMP and RS. ALP activity was measured after 4 days. Results from a representative of three experiments are reported as mean Ϯ SD of quadruplicate determinations, normalized to protein concentrations (*p Ͻ 0.005 for BMP ϩ RS vs. BMP ϩ RS ϩ SC). (H) M2 cells were treated in osteogenic medium with RS oxysterol combination (2.5 M) alone or in combination with COX-1 inhibitor SC-560 (SC, 10 M) and PGE 2 (1 M). ALP activity was measured after 4 days and reported as described above. Results from a representative of three experiments are reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentrations (*p Ͻ 0.01 for RS vs. RS ϩ SC and RS ϩ SC and RS ϩ SC ϩ PGE 2 ). (I) M2 cells were treated in osteogenic medium with RS oxysterol combination (2.5 M) alone or in combination with PLA 2 inhibitor ACA (25 M) and arachidonic acid (AA, 25 M). ALP activity was measured as described above. Results from a representative of three separate experiments are reported as the mean Ϯ SD of quadruplicate determinations, normalized to protein concentration (*p Ͻ 0.01 for RS vs. RS ϩ ACA and for RS ϩ ACA and RS ϩ ACA ϩ AA).
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Mechanism of anti-adipogenic activity of oxysterols
As noted above, ERKs are important in the proliferation and osteogenic differentiation of MSCs. In addition to positively regulating the osteogenic activity of osteoblast progenitor cells, ERK activation also negatively regulates the adipogenic differentiation of adipocyte progenitor cells, and inhibition of ERK enhances adipogenic differentiation. (49 -51) Consistent with this effect of ERK, inhibition of oxysterol-induced ERK activation by ERK pathway inhibitor PD98059 completely abolished the anti-adipogenic effects of 20S and 22S on Tro-induced adipogenesis in M2 cells (Fig. 5D) . Interestingly, PD98059 potentiated the adipogenic effects of Tro (Fig. 5D) , suggesting that, similar to the situation in pre-adipocytes, (51) spontaneous activity of ERK is inhibitory to the adipogenic differentiation of MSC. In contrast, the selective inhibitors for COX-1 and COX-2, SC-560, and NS-398, respectively, were not able to abolish the anti-adipogenic effects of the oxysterols (data not shown). These results suggested that the anti-adipogenic activity of oxysterols is mediated through activation of the ERK pathway.
DISCUSSION
This is the first demonstration of the ability of oxysterols to regulate lineage-specific differentiation of MSCs in favor of osteoblastic and against adipogenic differentiation. This effect of the oxysterols is in part mediated through COX/ PLA 2 -and ERK-dependent mechanisms (Fig. 6) . COX-1 and COX-2 are both present in osteoblastic cells and seem to be primarily involved in bone homeostasis and repair, respectively. (42, 52) Metabolism of arachidonic acid into prostaglandins, including prostaglandin E 2 (PGE 2 ), by the COXs mediates the osteogenic effects of these enzymes. (53) COX products and BMP2 have complementary and additive osteogenic effects. (44) Activation of PLA 2 releases arachidonic acid from cellular phospholipids and makes it available for further metabolism by COX enzymes into prostaglandins. (54, 55) Consistent with previous reports of oxysterol-stimulated metabolism of arachidonic acid, (56, 57) the present results suggest that the osteogenic activity of the oxysterols in MSC are in part mediated by the activation of PLA 2 -induced arachidonic acid release and its metabolism into osteogenic prostanoids by the COX pathway. Furthermore, COX activity also seems to be important in regulating the synergism between the osteogenic oxysterols and BMP2, but not in the anti-adipogenic effects of the oxysterols, suggesting the specific role of COX/PLA 2 pathway in mediating the oxysterol-induced lineage specific differentiation of M2 cells into osteogenic cells.
These results also show another signaling pathway mediating M2 responses to oxysterols is the ERK pathway. Sustained activation of ERKs mediates the osteogenic differentiation of human MSCs, (45) and activation of ERKs in 
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human osteoblastic cells results in upregulation of expression and DNA binding activity of Cbfa1, the master regulator of osteogenic differentiation. (46) Furthermore, ERK activation seems to be essential for growth, differentiation, and proper functioning of human osteoblastic cells. (58) In addition, the ERK pathway is a negative regulator of adipogenic differentiation of adipocyte progenitor cells. (49 -51) Consistent with the role of the ERK pathway in both osteogenic and adipogenic differentiation, oxysterol-induced mineralization and inhibition of adipogenic differentiation were blocked by the inhibitor, PD98059, and the oxysterols induced a sustained activation of ERK. It must be noted that, because both individual and combinations of oxysterols activated ERK, whereas only the combinations of oxysterols were able to induce full osteogenic differentiation of M2 cells, ERK activation seems to be an essential but not sufficient step in mediating the osteogenic effects of the oxysterols.
We also show for the first time that the osteogenic oxysterols synergistically stimulate BMP2-induced osteogenic differentiation of MSCs. It is of interest that when BMPs were originally extracted from bone matrix, they were found to be associated with lipids. (59) These crudely characterized lipids potentiated the osteogenic effects of BMP, as evidenced by a great reduction in the bone forming activity of BMP on their removal. (59) This line of evidence and the previous demonstration of the presence of lipids in healing fracture callus (60) suggest that lipids such as oxysterols may play an important role in regulating osteogenesis and the effects of BMP on this process. These studies suggest that specific oxysterols may potentiate the osteogenic differentiation of osteoblast precursor cells and that this effect of oxysterols is in part mediated through a potentiation of the osteogenic activity of BMPs. Furthermore, the synergistic effects of osteogenic oxysterols with BMP2 may provide an exciting new strategy for using BMP2 in local stimulation of fracture healing. However, because bone turnover is regulated by a combination of osteoblastic bone formation and osteoclastic bone resorption, it is important to note that the putative in vivo osteogenic capacity of oxysterol combinations reported here will depend also on their effect on osteoclastic differentiation/activity and bone resorption.
The possibility of inducing lineage-specific differentiation of MSCs into designated cells and tissues has potential implications for the prevention and treatment of a number of disorders that result from age-related tissue deterioration or from genetic defects. (6) For example, as noted earlier, agerelated osteoporosis seems to be, at least in part, caused by a decreased osteogenic differentiation of osteoprogenitor cells. (61) (62) (63) Accordingly, the focus of developing new therapeutic approaches that would positively impact osteoporosis has largely shifted from finding additional antiresorption agents to finding anabolic agents that can enhance bone formation. (15, 16) The possible use of lipid-based treatments involving oxysterols, rather than protein-or peptide-based interventions as currently used, introduces a whole new strategy for creating therapeutics that would potentially intervene in osteoporosis. Further identification of the downstream targets of these molecules in MSCs holds great potential for discovering new and previously unsuspected ways to regulate the lineage-specific differentiation of key MSC populations. This could improve the potential for the use of autologous MSCs in treatment of a variety of connective tissue diseases, as well as in tissue engineering. (6) In addition, fat cells increase significantly in mesenchymal tissues with age, in parallel with a decline in osteoblasts, muscle cells, and other key derivatives of MSCs. (64) The basis of this apparent shift in MSC differentiation is unknown, but the ability to reverse this process could significantly affect the management of age-related disorders.
